COGNITION / PEPTIDE CARD

Semax

A synthetic ACTH-derived peptide investigated for neurologic and cognitive effects, with limited generalizable human evidence.

PEPTIDE CARDSemax

Reviewed
August 8, 2026

Human evidence

2/5 · Limited regional trials

U.S. FDANot FDA approved

2026 WADANot specifically named

Inspect 3 sources

On this page

WHAT THE EVIDENCE SAYS

Semax evidence summary.

Semax has some human research, but the evidence is too limited and geographically concentrated to support broad cognitive-enhancement or neuroprotection claims.

Entity type
Peptide analogSource snapshot
August 8, 2026Record status
Sources attached

Do not overread this record

A published clinical study does not substitute for independent replication, transparent product characterization, and modern regulatory review.

01 / CLASSIFICATION

What is Semax?

Entity typePeptide analog

Research categoryCognition

Known namesSemax

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Neuroactive research peptides Goal: Cognition & Sleep

02 / EVIDENCE

Semax human and preclinical evidence.

HUMAN

2/5 · Limited regional trials

Small and regionally concentrated neurologic studies exist, but they do not provide a broad, independently replicated clinical program.

PRECLINICAL

3/5 · Neurobiology models

Animal and molecular studies explore neurotrophic, ischemic, and cognitive pathways.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Semax FDA and sport status.

U.S. FDANo FDA-approved Semax drug product; FDA identifies immunogenicity and peptide-impurity concerns for compounded Semax products.

2026 WADANot specifically named in the 2026 WADA List; athletes should verify current status and product contents.

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Semax being studied for?

01Ischemic stroke

02Neurotrophic signaling

03Cognition

04ACTH-derived peptides

05 / COMPARISONS

Compare Semax.

Semax vs SelankTwo neuroactive research peptides compared without treating regional studies as settled evidence.Semax vs DSIPLimited neurologic research compared with a very small historical sleep-peptide record.

06 / LATEST & DEFINING SOURCES

Semax primary and official sources.

Human trial / 2018Semax in acute ischemic stroke

PubMed

FDA / 2026Bulk substances that may present significant safety risks

U.S. FDA

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about Semax.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Semax?

Semax has some human research, but the evidence is too limited and geographically concentrated to support broad cognitive-enhancement or neuroprotection claims.

ResearchWhat is Semax being studied for?

Current source-backed research areas include Ischemic stroke, Neurotrophic signaling, Cognition, ACTH-derived peptides. These areas describe investigation, not established personal benefit.

FDA statusIs Semax FDA approved?

Current U.S. status for Semax: No FDA-approved Semax drug product; FDA identifies immunogenicity and peptide-impurity concerns for compounded Semax products.

Sport statusIs Semax prohibited in sport?

Current sport-status snapshot for Semax: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.

Evidence limitsWhat are the main evidence limits for Semax?

A published clinical study does not substitute for independent replication, transparent product characterization, and modern regulatory review.